Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Adicet Bio, Inc.

< Previous 1 2 3 Next >
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.